Vaccine Safety: Real and Perceived Issues

The Vaccine Book

Volumn , Issue , 2003, Pages 371-389

  Halsey, Neal A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890175484     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012107258-2/50028-7     Document Type: Chapter

References (92)

1. Lane J.M., Ruben F., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. J. Infect. Dis. 1970, 122:303-309.
2. Centers for Disease Control and Prevention Recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. Vaccinia (Smallpox) Vaccine. Morbidity and Mortality Weekly Report 2001, 50(No. RR-10):1-26.
3. Halsey N.A., Hyman S.L. Measles-mumps-rubella vaccine and autistic spectrum disorder: Report from the New Challenges in Childhood Immunizations Conference convened. Pediatrics 2001, 107:E84. 5.
4. Kroger L., Korppi M., Brander E., et al. Osteitis caused by bacillus Calmette-Guerin vaccination: A retrospective analysis of 222 cases. J. Infect. Dis. 1995, 172:574-576.
5. Siegel M.M., Walter T.K., Ablin A.R. Measles pneumonia in childhood leukemia. Pediatrics 1997, 60:38-40.
6. Centers for Disease Control and Prevention Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR 1996, 45(28):603-606.
7. Cermelli C., Jacobson S. Viruses and Multiple Sclerosis [Review]. Viral Immunol. 2000, 13(3):255-267.
8. Fredricks D.N., Relman D.A. Application of polymerase chain reaction to the diagnosis of infectious diseases. Clin. Infect. Dis. 1999, 29:475-486.
9. Fredricks D.N., Relman D.A. Application of polymerase chain reaction to the diagnosis of infectious diseases. Clin. Infect. Dis. 1999, 29:487-488.
10. Johnson R.T. Inflammatory and demyelinating diseases. Viral Infections of the Nervous System 1998, 227-264. Lippincott-Raven Publishers, Philadelphia, PA. 2nd ed.
11. Martin C.M. Am. J. Dis. Children 1963, 106:270.
12. Watson J.C., Hadler S.C., Dykewicz C.A., Reef S., Phillips L. Measles, mumps, and rubella-Vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1998, 47(RR-8):1-57.
13. Ellenberg S.S. Evaluating the Safety of Combination Vaccines. CID 2000, 33(Suppl. 4):S319-S322.
14. Silvers L.E., Ellenberg S.S., Wise R.P., Varricchio F.E., Mootrey G.T., Salive M.E. The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997. Pharmacoepidemiol. Drug Safety 2001, 10(4):279-285.
15. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A., et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994, 12:542-550.
16. Rennels M.B., Parashar U.D., Holman R.C., et al. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr. Infect. Dis. J. 1998, 17:924-925.
17. Niu M.T., Erwin D.E., Braun M.M. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): Early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001, 19(32):4627-4634.
18. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., Zanardi L.R., Setia S., Fair E., LeBaron C.W., Wharton M., Livingood J.R. Intussusception among infants given an oral rotavirus vaccine. New England J. Medicine 2001, 344(8):564-572.
19. Black S. Perspectives on the Design and Analysis of Prelicensure Trials: Bridging the Gap to Postlicensure Studies. Clin. Infect. Dis. 2001, 33(Suppl. 4):S323-S326.
20. Chen R.T., DeStefano F., Davis R.L., Jackson L.A., Thompson R.S., Mullooly J.P., et al. The Vaccine Safety Datalink: Immunization research in health maintenance organizations in the USA. Bull. WHO 2000, 78:186-194.
21. Chen R.T., Pool V., Takahashi H., Weniger B.G., Patel B. Combination Vaccines: Postlicensure Safety Evaluation. CID 2001, 33(Suppl. 4):S327-S333.
22. McPhillips H.A., Davis R.L., Marcuse E.K., Taylor J.A. The rotavirus vaccine's withdrawal and physicians' trust in vaccine safety mechanisms. Arch. Pediatr. Adolesc. Med. 2001, 155(9):1051-1056.
23. Nadler J.P. Multiple Sclerosis and Hepatitis B Vaccination. CID 1993, 17:928-929.
24. Pirmohamed M., Winstanley P. Hepatitis B Vaccine and neurotoxicity. Postgrad. Med. J. 1997, 73(861):462-463.
25. Tourbah A., Gout O., Liblau R., Lyon-Caen O., Bougniot C., Iba-Zizen M.T., Cabanis E.A. Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS?. Neurology 1999, 53:396-401.
26. Kaplanski G., Retornaz F., Durand J.M., Soubeyrand J. Central Nervous System Demyelination After Vaccination Against Hepatitis B and HLA Haplotype [letter]. J. Neurol. Neurosurg. Psychiatry 1995, 58(6):758-759.
27. Angell M. Evaluating the health risks of breast implants: The interplay of medical science, the law, and public opinion. New England J. Medicine 1996, 334:1513-1518.
28. Hulka B.S., Kerkvliet N.L., Tugwell P. Sounding Board: Experience of a Scientific Panel Formed to Advise the Federal Judiciary on Silicone Breast Implants [Editorial]. New England J. Medicine 2000, 342(11):812-815.
29. Janowski E.C., Kupper L.L., Hulka B.S. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. New England J. Med. 2000, 342(11):781-790.
30. Alper P.R., Borzelleca J.F., Botts M.K., et al. Silicone Breast implants: Why Has Science Been Ignored? 1997, 1998, available at URL, American Council on Science and Health, Brochure. http://www.acsh.org/publications/booklets/implants.html.
31. Reis E.C., Jacobson R.M., Tarbell S., Weniger B.G. Taking the sting out of shots: Control of vaccination-associated pain and adverse reactions. Pediatr. Ann. 1998, 27(6):375-386.
32. Barnhill B.J., Holbert M.D., Jackson N.M., Erickson R.S. Using pressure to decrease the pain of intramuscular injections. J. Pain Symptom Manage. 1996, 12(1):52-58.
33. French G.M., Painter E.C., Coury D.L. Blowing away shot pain: A technique for pain management during immunization. Pediatrics 1994, 93(3):384-388.
34. Braun M.M., Patriarca P.A., Ellenberg S.S. Syncope after immunization. Arch. Pediatr. Adolesc. Med. 1997, 151(3):255-259.
35. American Academy of Pediatrics 2000 Red Book: Report of the Committee on Infectious Diseases 2000, American Academy of Pediatrics, Elk Grove Village, IL. 25th ed. L.K. Pickering (Ed.).
36. WHO Guidelines on vaccine administration sites.
37. Centers for Disease Control and Prevention General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR 1994, 43(No. RR-01):1-38.
38. Centers for Disease Control and Prevention Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination. Recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report 1991, 48(No. RR-13):1-25.
39. Strebel P.M., Ion-Nedelcu N., Baughman A.L., Sutter R.W., Cochi S.L. Intramuscular Injections Within 30 Days of Immunization with Oral Poliovirus Vaccine-A Risk Factor for Vaccine-Associated Paralytic Poliomyelitis. New England J. Med. 1995, 332(8):500-530.
40. World Health Organization Vaccine supply and quality: Surveillance of adverse events following immunization. Weekly Epidemiol. Record 1996, 71(No. 32):237-244.
41. Bernier R.H., Frank J.A., Nolan T.F. Abscesses complicating DTP vaccination. Am. J. Dis. Child. 1981, 135(9):826-828.
42. Nathanson N., Langmuir A. The Cutter Incident: Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. I Background. Am. J. Hyg. 1963, 78:16-28.
43. Nathanson N., Langmuir A. The Cutter Incident: Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. Am. J. Hyg. 1963, 78:29-60.
44. Nathanson N., Langmuir A. The Cutter Incident: Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. III. Comparison of the clinical character of vaccinated and contact cases occurring after use of high rate lots of Cutter vaccine. Am. J. Hyg. 1963, 78:61-81.
45. Parkman P.D., Hardegree M.C. Regulation and Testing of Vaccines. Vaccines 1999, 1131. W.B. Saunders Company, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
46. Ebbert G.B., Mascolo E.D., Six H.R. Overview of Vaccine Manufacturing and Quality Assurance. Vaccines 1999, 40. W.B. Saunders Company, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
47. Centers for Disease Control and Prevention Prevention of Varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report 1996, 45(No. RR-11):1-36.
48. Smith K.C., Starke J.R. Bacille Calmette-Guerin Vaccine. Vaccines 1999, 111. W.B. Saunders Company, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
49. Strebel P.M., Sutter R.W., Cochi S.L., Biellik R.J., Brink E.W., Kew O.M., et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 1992, 14:568-579.
50. Mortimer E.A., Lepow M.L., Gold E., Robbins F.C., Burton G.J., Fraumeni J.F. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. New England J. Med. 1981, 305(25):1517-1518.
51. Shah K.V. Does SV40 infection contribute to the development of human cancers?. Rev. Med. Virol. 2000, 10(1):31-43.
52. Williams G. Hepatitis and Hell to Pay. Virus Hunters 1959, Alfred A. Knopf, New York. 1st ed.
53. Monath T.P. Yellow Fever. Vaccines 1999, 815. W.B. Saunders Company, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
54. Marwick C. FDA calls bovine-based vaccines currently safe. J. Am. Med. Assoc. 2000, 284(10):1231-1232.
55. Public Health Service Notice to Readers: Public Health Service Recommendations for the use of Vaccines Manufactured with Bovine-Derived Materials. Morbidity and Mortality Weekly Report 2000, 49(50):1137-1138.
56. Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development. Proceedings of an International Association of Biologicals Symposium, September 7-10, 1999, Rockville, MD 2001, Karger, Basel, Switzerland. F. Brown, A.M. Lewis, K. Peden, P. Krause (Eds.).
57. Steinhoff M.C., Reed G.F., Decker M.D., Edwards K.M., Englund J.A., Pichichero M.E., Rennels M.B., Anderson E.L., Deloria M.A., Meade B.D. A randomized comparison of reactogenicity and immunogenicity of two whole cell pertussis vaccines. Pediatrics 1995, 96:567-570.
58. Edelman R. Adjuvants for the Future. New Generation Vaccines 1997, 137-192. Marcel Dekker, New York. 2nd ed. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon (Eds.).
59. Ball L.K., Ball R., Pratt R.D. An Assessment of Thimerosal Use in Childhood Vaccines. Pediatrics 2001, 107:1147-1154.
60. AAP and PHS Joint Statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (PHS). Pediatrics 1999, 104:568-569.
61. Stratton, K., Gable, A., and McCormick, M. C., Eds., "Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders." Washington, DC: National Academy Press.
62. Freed G.L. History of Thimerosal Concern and Comparative Policy Actions. Presented at Thimerosal-Containing Vaccines and Neurodevelopmental, Outcomes (sponsored by IOM) 2001.
63. Halsey N.A., Goldman L. Balancing risks and benefits: Primum non nocere is too simplistic. Pediatrics 2001, 108(2):466-467.
64. Institute of Medicine Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality 1994, National Academy Press, Washington, DC.
65. Mortimer E.A., Ball R., Ball L.K., Wise R.P., Braun M.M., Beeler J.A., Salive M.E. Stevens-Johnson Syndrome after Vaccination. Pediatr. Infect. Dis. J. 2001, 20(8):818-819.
66. Kelso J.M., Jones R.T., Yunginger J.W. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. Allergy Clin. Immunol. 1993, 91(4):867-872.
67. Sakaguchi M., Nakayama T., Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J. Allergy Clin. Immunol. 1996, 98(6 Pt. 1):1058-1061.
68. James J.M., Burks A.W., Roberson P.K., Sampson H.A. Safe administration of the measles vaccine to children allergic to eggs. New England J. Med. 1995, 332(19):1262-1266.
69. Greenberg M.A., Birx D.L. Safe administration of mumps-measles-rubella vaccine in egg-allergic children. J. Pediatr. 1988, 113(3):504-506.
70. Centers for Disease Control and Prevention Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report 2001, 50(No. RR-04):1-36.
71. Hurwitz E.S., Schonberger L.B., Nelson D.B., Holman R.C. Guillain-Barre syndrome and the 1978-1979 influenza vaccine. New England J. Med. 1981, 304(26):1557-1561.
72. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., Clark S., Haber P., Stolley P.D., Schonberger L.B., Chen R.T. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. New England J. Med. 1998, 339(25):1797-1802.
73. Centers for Disease Control and Prevention Measles pneumonitis following measlesmumps-rubella vaccination of a patient with HIV infection, 1993. MMWR 1996, 45(28):603-606.
74. Moss W.J., Halsey N.A. Immunization of HIV-infected Children. Bull. WHO 2001, in press.
75. Msellati P., et al. BCG vaccination and pediatric HIV infection-Rwanda, 1988-1990. Morbidity and Mortality Weekly Report 1991, 40(48):833-836.
76. Bhat G.J., Diwan V.K., Chintu C., Kabika M., Masona J. HIV, BCG and TB in children: A case control study in Lusaka, Zambia. J. Trop. Pediatr. 1993, 39(4):219-223.
77. Sharrar R.G., LaRussa P., Galea S.A., Steinberg S.P., Sweet A.R., Keatley R.M., Wells M.E., Stephenson W.P., Gershon A.A. The postmarketing safety profile of varicella vaccine. Vaccine 2000, 19(7-8):916-923.
78. Fujinami R.S., Oldstone M.B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity. Science 1985, 230(4729):1043-1045.
79. Confavreux C., Suissa S., Saddier P., Bourdes V., Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. New England J. Med. 2001, 344(5):319-326.
80. Classen J.B. The timing of immunization affects the development of diabetes in rodents. Autoimmunity 1996, 24(3):137-145.
81. LaPorte R.E., Matusushima M., Change Y.F. Prevalence and incidence of insulin-dependent diabetes. NIH Publication 95-1468 1997, 37-46. National Diabetes Data Group of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. 2nd ed. M.I. Harris, C.C. Cowie, M.P. Stern, E.J. Loyko, G.E. Reiber, P.H. Bennett (Eds.).
82. Karvonen M., Cepaitis Z., Tuomilehto J. Association between type 1 diabetes and Haemophilus influenzae type b vaccination: Birth cohort study. Br. Med. J. 1999, 318:1169-1172.
83. Institutes for Vaccine Safety Childhood immunizations and type 1 diabetes: summary of an Institute for Vaccine Safety Workshop. Pediatr. Infect. Dis. J. 1999, 18:217-222.
84. Childhood Immunization Schedule and Diabetes: An Unfounded Hypothesis. Clin. Infect. Dis. 1998, 27(2). hot page.
85. Wakefield A.J., Murch S.H., Anthony A., Linnell J., Casson D.M., Malik M., Berelowitz M., Dhillon A.P., Thomson M.A., Harvey P., Valentine A., Davies S.E., Walker-Smith J.A. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998, 351(9103):637-641.
86. Wakefield A.J., Montgomery S.M., Pounder R.E. Crohn's disease: The case for measles virus. Ital. J. Gastroenterol. hepatol. 1999, 31:247-254.
87. Institute of Medicine Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental, Disorders 2001, National Academy Press, Washington DC. K. Stratton, A. Gable, M.C. McCormick (Eds.).
88. Afzal M.A., Minor P.D., Ghosh S., Jin L. Measles virus persistence in specimens of inflammatory bowel disease and autism cases. Dig. Dis. Sci. 2001, 46(3):658-660.
89. Taylor B., Miller E., Farrington C.P., et al. Autism and measles, mumps and rubella vaccine: No epidemiological evidence for a causal association. Lancet. 1999, 353:2026-2029.
90. Kaye J.A., del mar Melero-Montes M., Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: A time trend analysis. Br. Med. J. 2001, 322:460-463.
91. Dales L., Hammer S.J., Smith N.J. Time Trends in Autism and in MMR Immunization Coverage in California. J. Am. Med. Assoc. 2001, 285:1183-1185.
92. McPhillips H., Marcuse E.K. Vaccine safety. Curr. Prob. Pediatr. 2001, 31(4):91-121.